A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
מצבים רפואיים
Healthy Participants · Healthy Subjects · Healthy Volunteers · Autoimmune Diseases · Healthy Adult Participants · Atopic Dermatitis · Prurigo Nodularis
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Innovate Clinical Research, Waitara, New South Wales, Australia
Cmax Clinical Research, Adelaide, South Australia, Australia
Peking University Third Hospital, Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China
Xiangya Hospital of Central South University, Changsha, Hunan, China
Suzhou Municipal Hospital, Suzhou, Jiangsu, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
The Affiliated Hospital of Qingdao University Branch West Coast, Qingdao, Shandong, China
Chengdu Second Peoples Hospital, Chengdu, Sichuan, China
Optimal Clinical Trials Ltd, Auckland, New Zealand
Pacific Clinical Research Network Auckland, Takapuna, New Zealand
Lakeland Clinical Trials Wellington, Upper Hutt, New Zealand
מובילי המחקר
Study Director
BeiGene